Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRL Stock Forecast 2026-2027
$176.94
Current Price
$8.73B
Market Cap
Buy 12
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to CRL Price Targets
+49.8%
To High Target of $265.00
+13.0%
To Median Target of $200.00
-23.7%
To Low Target of $135.00
CRL Price Momentum
+0.7%
1 Week Change
+15.1%
1 Month Change
+66.8%
1 Year Change
-11.3%
Year-to-Date Change
-22.7%
From 52W High of $228.88
+77.3%
From 52W Low of $99.80
📊 TOP ANALYST CALLS
Did CRL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Charles River is one of their latest high-conviction picks.
Latest CRL Stock Price Targets & Analyst Predictions
Based on our analysis of 33 Wall Street analysts, CRL has a bullish consensus with a median price target of $200.00 (ranging from $135.00 to $265.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $176.94, the median forecast implies a 13.0% upside. This outlook is supported by 12 Buy, 5 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Patrick Donnelly at Citigroup, projecting a 49.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRL Analyst Ratings
12
Buy
5
Hold
1
Sell
CRL Price Target Range
Low
$135.00
Average
$200.00
High
$265.00
Current: $176.94
Latest CRL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 14, 2026 | Barclays | Luke Sergott | Overweight | Maintains | $210.00 |
| Apr 13, 2026 | JP Morgan | Casey Woodring | Neutral | Maintains | $160.00 |
| Feb 25, 2026 | UBS | Dan Leonard | Neutral | Maintains | $175.00 |
| Feb 20, 2026 | TD Cowen | Charles Rhyee | Buy | Maintains | $235.00 |
| Feb 20, 2026 | Mizuho | Ann Hynes | Neutral | Maintains | $175.00 |
| Feb 19, 2026 | Evercore ISI Group | Ross Muken | Outperform | Maintains | $200.00 |
| Feb 19, 2026 | Barclays | Luke Sergott | Overweight | Maintains | $200.00 |
| Jan 16, 2026 | Citigroup | Patrick Donnelly | Buy | Maintains | $265.00 |
| Jan 13, 2026 | Evercore ISI Group | Ross Muken | Outperform | Maintains | $260.00 |
| Dec 18, 2025 | Mizuho | Ann Hynes | Neutral | Maintains | $200.00 |
| Dec 15, 2025 | JP Morgan | Casey Woodring | Neutral | Maintains | $190.00 |
| Dec 15, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $215.00 |
| Nov 11, 2025 | Morgan Stanley | Ricky Goldwasser | Equal-Weight | Maintains | $185.00 |
| Nov 10, 2025 | TD Cowen | Charles Rhyee | Buy | Maintains | $197.00 |
| Nov 6, 2025 | Baird | Eric Coldwell | Outperform | Upgrade | $199.00 |
| Nov 6, 2025 | JP Morgan | Casey Woodring | Neutral | Maintains | $165.00 |
| Nov 6, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $210.00 |
| Oct 17, 2025 | Mizuho | Ann Hynes | Neutral | Maintains | $174.00 |
| Oct 6, 2025 | William Blair | Matt Larew | Outperform | Upgrade | $N/A |
| Oct 3, 2025 | Evercore ISI Group | Ross Muken | Outperform | Maintains | $200.00 |
Charles River Laboratories International, Inc. (CRL) Competitors
The following stocks are similar to Charles River based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CRL
Charles River
mkt cap
8.67B
Charles River Laboratories International, Inc. (CRL) Financial Data
Charles River Laboratories International, Inc. has a market capitalization of $8.73B with a P/E ratio of 681.3x. The company generates $4.02B in trailing twelve-month revenue with a -3.6% profit margin.
Revenue growth is -0.8% quarter-over-quarter, while maintaining an operating margin of +4.5% and return on equity of -4.2%.
Valuation Metrics
Market Cap
$8.73B
Enterprise Value
$11.35B
P/E Ratio
681.3x
PEG Ratio
20.5x
Price/Sales
2.2x
Growth & Margins
Revenue Growth (YoY)
-0.8%
Gross Margin
+31.1%
Operating Margin
+4.5%
Net Margin
-3.6%
EPS Growth
-0.8%
Financial Health
Cash/Price Ratio
+2.5%
Current Ratio
1.3x
Debt/Equity
81.9x
ROE
-4.2%
ROA
+4.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Charles River Laboratories International, Inc. (CRL) Business Model
About Charles River Laboratories International, Inc.
What They Do
Provider of services for drug discovery and development.
Business Model
The company operates through three main segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. It generates revenue by supplying animal models, conducting regulatory-required safety tests, and offering microbial and biologics solutions for companies in the pharmaceutical, biotechnology, and medical device sectors.
Additional Information
Founded in 1947 and headquartered in Wilmington, Massachusetts, the company serves a global market, emphasizing high-quality and compliant research and testing services critical to the life sciences industry.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
18,700
CEO
Mr. James C. Foster J.D.
Country
United States
IPO Year
2000
Website
www.criver.comCharles River Laboratories International, Inc. (CRL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Apr 14, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Charles River (CRL) has a strong history of earnings surprises and the factors indicating a potential earnings beat in the upcoming quarterly report.
Why It Matters
Charles River's strong earnings surprise history and favorable indicators suggest potential for a positive earnings report, which can boost investor confidence and stock price.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
The recommended strategy for investing in these stocks is to purchase a diversified selection rather than just one or two, to minimize single-stock risk.
Why It Matters
Diversifying investments across multiple stocks reduces single-stock risk, potentially leading to more stable returns and lower volatility in an investor's portfolio.
Source: Barrons
Market Sentiment:
Positive
Quick Summary
Charles River Laboratories (NYSE: CRL) has partnered with the American Heart Association to enhance awareness and prevention initiatives for cardiovascular disease.
Why It Matters
The collaboration enhances Charles River Laboratories' reputation and potential for revenue growth in the healthcare sector, signaling positive momentum for the company's stock.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
The NYSE has launched a daily pre-market advisory to provide updates directly from the trading floor, effective April 6, 2026.
Why It Matters
The NYSE's pre-market updates can influence investor sentiment and trading strategies, impacting stock prices and market movement before the official market opens.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Charles River (CRL) reported earnings 30 days ago; investors may look for upcoming developments or analyses to gauge future stock performance.
Why It Matters
Earnings reports can influence stock performance; upcoming developments or guidance can affect investor sentiment and stock price volatility for Charles River.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Charles River Laboratories (CRL) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting key insights relevant to investors in the healthcare sector.
Why It Matters
CRL's presentation at a major healthcare conference may indicate strategic initiatives, potential partnerships, or market insights, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About CRL Stock
What is Charles River Laboratories International, Inc.'s (CRL) stock forecast for 2026?
Based on our analysis of 33 Wall Street analysts, Charles River Laboratories International, Inc. (CRL) has a median price target of $200.00. The highest price target is $265.00 and the lowest is $135.00.
Is CRL stock a good investment in 2026?
According to current analyst ratings, CRL has 12 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $176.94. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRL stock?
Wall Street analysts predict CRL stock could reach $200.00 in the next 12 months. This represents a 13.0% increase from the current price of $176.94. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Charles River Laboratories International, Inc.'s business model?
The company operates through three main segments: Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. It generates revenue by supplying animal models, conducting regulatory-required safety tests, and offering microbial and biologics solutions for companies in the pharmaceutical, biotechnology, and medical device sectors.
What is the highest forecasted price for CRL Charles River Laboratories International, Inc.?
The highest price target for CRL is $265.00 from Patrick Donnelly at Citigroup, which represents a 49.8% increase from the current price of $176.94.
What is the lowest forecasted price for CRL Charles River Laboratories International, Inc.?
The lowest price target for CRL is $135.00 from at , which represents a -23.7% decrease from the current price of $176.94.
What is the overall CRL consensus from analysts for Charles River Laboratories International, Inc.?
The overall analyst consensus for CRL is bullish. Out of 33 Wall Street analysts, 12 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $200.00.
How accurate are CRL stock price projections?
Stock price projections, including those for Charles River Laboratories International, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 3:33 AM UTC